IL300586A - SARM1 inhibitors - Google Patents

SARM1 inhibitors

Info

Publication number
IL300586A
IL300586A IL300586A IL30058623A IL300586A IL 300586 A IL300586 A IL 300586A IL 300586 A IL300586 A IL 300586A IL 30058623 A IL30058623 A IL 30058623A IL 300586 A IL300586 A IL 300586A
Authority
IL
Israel
Prior art keywords
ring
nitrogen
compound
compound according
sulfur
Prior art date
Application number
IL300586A
Other languages
English (en)
Hebrew (he)
Original Assignee
Disarm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disarm Therapeutics Inc filed Critical Disarm Therapeutics Inc
Publication of IL300586A publication Critical patent/IL300586A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL300586A 2020-08-24 2021-08-23 SARM1 inhibitors IL300586A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063069408P 2020-08-24 2020-08-24
US202163142398P 2021-01-27 2021-01-27
PCT/US2021/047093 WO2022046606A1 (en) 2020-08-24 2021-08-23 Inhibitors of sarm1

Publications (1)

Publication Number Publication Date
IL300586A true IL300586A (en) 2023-04-01

Family

ID=77775005

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300586A IL300586A (en) 2020-08-24 2021-08-23 SARM1 inhibitors

Country Status (18)

Country Link
US (2) US12043613B2 (cg-RX-API-DMAC7.html)
EP (1) EP4200293A1 (cg-RX-API-DMAC7.html)
JP (2) JP7349046B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230057396A (cg-RX-API-DMAC7.html)
AU (2) AU2021333558C1 (cg-RX-API-DMAC7.html)
BR (1) BR112023002575A2 (cg-RX-API-DMAC7.html)
CA (1) CA3189181A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000525A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023001975A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230113A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000038A (cg-RX-API-DMAC7.html)
EC (1) ECSP23012981A (cg-RX-API-DMAC7.html)
IL (1) IL300586A (cg-RX-API-DMAC7.html)
MX (1) MX2023002256A (cg-RX-API-DMAC7.html)
PE (1) PE20230737A1 (cg-RX-API-DMAC7.html)
TW (2) TWI786777B (cg-RX-API-DMAC7.html)
WO (1) WO2022046606A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202301801B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12083114B2 (en) 2018-12-19 2024-09-10 Disarm Therapeutics, Inc. Inhibitors of SARM1 in combination with neuro-protective agents
EP4192828A1 (en) 2020-08-04 2023-06-14 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
WO2022060812A1 (en) 2020-09-16 2022-03-24 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
MX2024001322A (es) 2021-07-28 2024-04-30 Nura Bio Inc Derivados de piridina sustituida como inhibidores de sarm1.
IL318437A (en) * 2022-07-21 2025-03-01 Amylyx Pharmaceuticals Inc Compositions containing oligonucleotides, and methods of using them
EP4634156A1 (en) * 2022-12-15 2025-10-22 Sironax Ltd Sarm1 modulators, preparations, and uses thereof
CN121002009A (zh) 2023-01-24 2025-11-21 达萨玛治疗公司 作为sarm1抑制剂的哒嗪类物
WO2024222835A1 (en) * 2023-04-27 2024-10-31 Sironax Ltd. Sarm1 modulators, preparations, and uses thereof
CN119219603A (zh) * 2023-06-28 2024-12-31 科辉智药(深圳)新药研究中心有限公司 Sarm1酶活性抑制剂及其用途
WO2025045746A1 (en) * 2023-08-25 2025-03-06 F. Hoffmann-La Roche Ag Pyrazole derivatives as sarm1 inhibitors useful for the treatment of neurodegenerative disorders
WO2025049184A1 (en) 2023-08-25 2025-03-06 Eli Lilly And Company (s)-3-((6-fluoropyridin-3-yl)methyl)-1-(5-(pyridin-4-yl)-4h-1,2,4-triazol-3-yl)piperidin-2-one benzenesulfonate
WO2025076017A1 (en) * 2023-10-05 2025-04-10 Genentech, Inc. Carbamates for use as sarm1 inhibitors
WO2025076088A1 (en) * 2023-10-05 2025-04-10 Genentech, Inc. Lactams for use as sarm1 inhibitors
WO2025157895A1 (en) 2024-01-25 2025-07-31 UCB Biopharma SRL Pyrrolidinone derivatives

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11193281A (ja) 1997-10-27 1999-07-21 Takeda Chem Ind Ltd アデノシンa3受容体拮抗剤およびチアゾール化合物
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US20040122016A1 (en) 2002-10-30 2004-06-24 Jingrong Cao Compositions useful as inhibitors of rock and other protein kinases
EP1581222A2 (en) 2003-01-02 2005-10-05 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr;
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
DE602005020611D1 (de) 2004-04-28 2010-05-27 Vertex Pharma Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
CA2591413A1 (en) 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
JP5244591B2 (ja) 2006-06-28 2013-07-24 あすか製薬株式会社 ピリジルイソオキサゾール誘導体
CN101516874A (zh) 2006-09-21 2009-08-26 诺瓦提斯公司 用于治疗细胞因子介导的疾病的吡咯衍生物
JP2011506563A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー ビスチアゾール誘導体、その製造方法および医薬品としてのその使用
BRPI0820722A2 (pt) 2007-12-20 2015-06-16 Novartis Ag Derivados de tiazol usados como inibidores de pi 3 cinases
TW201004941A (en) 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
US8785468B2 (en) 2009-02-13 2014-07-22 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
US20120328629A1 (en) 2011-06-24 2012-12-27 University Of Miami Therapeutic Applications Targeting SARM1
WO2014070978A1 (en) 2012-11-03 2014-05-08 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
EP2934536B1 (en) 2012-12-19 2017-09-27 Merck Sharp & Dohme Corp. FACTOR IXa INHIBITORS
RU2570907C2 (ru) 2013-10-21 2015-12-20 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа.
WO2015084936A1 (en) 2013-12-04 2015-06-11 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
EP4091622A1 (en) 2016-08-16 2022-11-23 Henry Ford Health System Compositions for the treatment of chemotherapy-induced neuropathic pain
US11253503B2 (en) 2016-09-24 2022-02-22 Washington University Inhibitors of SARM1 NADase activity and uses thereof
UY37512A (es) 2016-12-09 2019-04-30 Vertex Pharma Compuestos pirazol 1,3-sustituido útiles para la reducción de los niveles de ácidos grasos de cadena muy larga
WO2018114663A1 (de) 2016-12-22 2018-06-28 Bayer Cropscience Aktiengesellschaft Substituierte azolylpyrrolone und azolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe
BR112019012822A2 (pt) * 2016-12-22 2019-11-26 Bayer Ag 1,2,4-tiadiazolilpirrolonas e 1,2,4-tiadiazolil-hidantoínas e sais das mesmas e uso das mesmas como herbicidas
EP3728230A1 (en) * 2017-12-22 2020-10-28 Ravenna Pharmaceuticals, Inc. Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2019236890A1 (en) * 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
CN112839648B (zh) * 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
US12338238B2 (en) 2018-06-07 2025-06-24 Disarm Therapeutics, Inc. Inhibitors of SARM1
WO2020158762A1 (ja) 2019-01-30 2020-08-06 武田薬品工業株式会社 複素環化合物
EP3980011B1 (en) 2019-06-06 2025-12-17 Disarm Therapeutics, Inc. Inhibitors of sarm1
CA3141404A1 (en) 2019-06-14 2020-12-17 Disarm Therapeutics, Inc. Inhibitors of sarm1
AU2020318591A1 (en) 2019-07-22 2022-02-17 Bayer Aktiengesellschaft 5-amino substituted pyrazoles and triazoles as pest control agents
EP4028013A4 (en) 2019-09-12 2023-10-18 Disarm Therapeutics, Inc. MRSA1 INHIBITORS
JP7712922B2 (ja) 2019-11-05 2025-07-24 デルミラ インコーポレイテッド 炎症性障害を治療するためのMrgprX2アンタゴニスト
MY206478A (en) 2020-01-07 2024-12-18 Disarm Therapeutics Inc Inhibitors of sarm1
US20230271957A1 (en) 2020-04-09 2023-08-31 Disarm Therapeutics, Inc. Condensed pyrazole derivatives as inhibitors of sarm1
JP7478252B2 (ja) 2020-04-09 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1の阻害剤
EP4192828A1 (en) * 2020-08-04 2023-06-14 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors

Also Published As

Publication number Publication date
TW202530197A (zh) 2025-08-01
AU2021333558C1 (en) 2024-06-20
AU2021333558B2 (en) 2024-02-22
CO2023001975A2 (es) 2023-03-07
CA3189181A1 (en) 2022-03-03
JP2024016014A (ja) 2024-02-06
EP4200293A1 (en) 2023-06-28
US20220056013A1 (en) 2022-02-24
CR20230113A (es) 2023-04-14
BR112023002575A2 (pt) 2023-03-07
WO2022046606A1 (en) 2022-03-03
ZA202301801B (en) 2024-09-25
PE20230737A1 (es) 2023-05-03
CL2023000525A1 (es) 2023-09-15
JP7349046B2 (ja) 2023-09-21
KR20230057396A (ko) 2023-04-28
TWI786777B (zh) 2022-12-11
AU2024203373A1 (en) 2024-06-13
US12043613B2 (en) 2024-07-23
US20240376083A1 (en) 2024-11-14
MX2023002256A (es) 2023-03-17
ECSP23012981A (es) 2023-03-31
TW202334117A (zh) 2023-09-01
AU2021333558A1 (en) 2023-03-02
TW202214597A (zh) 2022-04-16
JP2023535236A (ja) 2023-08-16
JP7756130B2 (ja) 2025-10-17
DOP2023000038A (es) 2023-03-15

Similar Documents

Publication Publication Date Title
IL300586A (en) SARM1 inhibitors
US12331033B2 (en) Inhibitors of SARM1
JP7319395B2 (ja) Sarm1の阻害剤
EP4132920B1 (en) Indazole derivatives as inhibitors of sarm1
EP4132928B1 (en) Condensed pyrazole derivatives as inhibitors of sarm1
JP7746384B2 (ja) Sarm1のベンゾピラゾール阻害剤
JP2022547707A (ja) Sarm1の阻害剤
EA048703B1 (ru) Ингибиторы sarm1
BR122025022748A2 (pt) Inibidores de sarm1, composições que os compreendem, usos dos mesmos, métodos para inibir sarm1, e combinações
CN116940569A (zh) Sarm1抑制剂